Regenxbio (NASDAQ:RGNX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Saturday.
According to Zacks, “REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. “
A number of other brokerages have also recently issued reports on RGNX. BidaskClub upgraded shares of Regenxbio from a “buy” rating to a “strong-buy” rating in a research note on Friday, December 22nd. Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a research note on Monday, December 11th. Raymond James Financial reiterated a “buy” rating on shares of Regenxbio in a research note on Friday, January 5th. TheStreet cut shares of Regenxbio from a “c” rating to a “d+” rating in a research note on Tuesday, November 28th. Finally, Barclays started coverage on shares of Regenxbio in a research note on Wednesday, November 22nd. They issued an “overweight” rating and a $38.00 price target on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $40.00.
Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, March 6th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.20. The company had revenue of $2.04 million for the quarter. Regenxbio had a negative net margin of 704.02% and a negative return on equity of 36.48%. equities analysts expect that Regenxbio will post -2.46 earnings per share for the current year.
In other Regenxbio news, CFO Vittal Vasista sold 5,000 shares of the company’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $30.00, for a total transaction of $150,000.00. Following the transaction, the chief financial officer now owns 87,277 shares in the company, valued at approximately $2,618,310. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Curran Simpson sold 30,000 shares of the company’s stock in a transaction dated Friday, December 22nd. The shares were sold at an average price of $33.03, for a total transaction of $990,900.00. Following the transaction, the senior vice president now owns 69,500 shares in the company, valued at approximately $2,295,585. The disclosure for this sale can be found here. Insiders have sold a total of 70,000 shares of company stock worth $2,148,100 in the last 90 days. Company insiders own 17.00% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of RGNX. Voya Investment Management LLC bought a new position in Regenxbio during the 2nd quarter valued at about $249,000. Teacher Retirement System of Texas bought a new position in Regenxbio during the 4th quarter valued at about $302,000. Wells Fargo & Company MN lifted its stake in Regenxbio by 1.1% during the 2nd quarter. Wells Fargo & Company MN now owns 16,209 shares of the biotechnology company’s stock valued at $320,000 after acquiring an additional 175 shares during the period. State Board of Administration of Florida Retirement System bought a new position in Regenxbio during the 3rd quarter valued at about $328,000. Finally, Nomura Asset Management Co. Ltd. bought a new position in Regenxbio during the 4th quarter valued at about $333,000. Institutional investors and hedge funds own 69.22% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Regenxbio (RGNX) Downgraded by Zacks Investment Research to “Hold”” was published by Ticker Report and is owned by of Ticker Report. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3252830/regenxbio-rgnx-downgraded-by-zacks-investment-research-to-hold.html.
Regenxbio Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.